Breast Cancer | Specialty

The OncLive Breast Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of breast cancer, including those that are triple negative, hormone receptor positive, and/or HER2 positive. This page features news articles, interviews in written and video format, and podcasts that focus on treatment advances and ongoing research in breast cancer.

Dr Meisel on Communication Barriers Between Patients and Oncologists in Breast Cancer

February 7th 2024

Jane L. Meisel, MD, discusses the rationale for evaluating communication challenges that currently exist between patients and their oncologists.

Ongoing Research and Unmet Needs in Patients With Breast Cancer and ESR1 Mutations

February 6th 2024

Drs Mayer and Kalinsky conclude their discussion with a look at agents in development and unmet needs for patients with breast cancer and ESR1 mutations.

HER2CLIMB-02: Randomized, Double-blind Phase 3 Trial of Tucatinib and Trastuzumab Emtansine for Previously Treated HER2-positive Metastatic Breast Cancer

February 5th 2024

Erika Hamilton, MD, presents data from the phase 3 HER2CLIMB-02 study investigating tucatinib and trastuzumab emtansine in patients with previously treated HER2+ metastatic breast cancer.

World Cancer Day Highlights Ways to Address Gaps in Care for Black Patients With Breast Cancer

February 4th 2024

World Cancer Day is held every year on February 4th, prompting individuals across the globe to expand awareness within cancer care.

Approaches to Repeat Hormone Receptor and HER2 Status Testing Before Initiating Later Lines of Therapy

February 2nd 2024

Laura Huppert, MD, and Yara Abdou, MD, review approaches to repeat hormone receptor and HER2 status testing before initiating later lines of therapy in patients with metastatic breast cancer.

The MAINTAIN Trial: Ribociclib in Combination With Endocrine Therapy in Patients With Metastatic Breast Cancer

February 2nd 2024

Laura Huppert, MD, and Yara Abdou, MD, discuss data from the MAINTAIN trial on ribociclib in combination with endocrine therapy in patients with metastatic breast cancer.

Overview of the Treatment Landscape for HR+, HER2- Advanced or Metastatic Breast Cancer

February 2nd 2024

Laura Huppert, MD, and Yara Abdou, MD, provide an overview of the treatment landscape for HR+, HER2- advanced or metastatic breast cancer.

Dr McAndrew on the Implications of the PHERGain Study in HER2+ Breast Cancer

February 1st 2024

Nicholas P. McAndrew, MD, MSCE, discusses the implications of the phase 2 PHERGain study of chemotherapy de-escalation in patients with HER2-positive early breast cancer.

SERENA-2: Camizestrant vs Fulvestrant in Advanced ER+/HER2- Breast Cancer

January 30th 2024

Medical oncologists discuss oral SERDs, with a focus on the SERENA-2 trial looking at camizestrant in patients with advanced ER+/HER2- breast cancer.

The Role of Elacestrant in Breast Cancer

January 30th 2024

Erica L. Mayer, MD, MPH, discusses the role of elacestrant in the breast cancer treatment landscape and provides clinical insights on its safety profile.

HER2CLIMB-02: Primary Analysis of a Randomized, Double-blind Phase 3 Trial of Tucatinib and Trastuzumab Emtansine for Previously Treated HER2-positive Metastatic Breast Cancer

January 25th 2024

Sara A. Hurvitz, MD, presents data from the phase 3 HER2CLIMB-02 study investigating tucatinib and trastuzumab emtansine in patients with previously treated HER2+ metastatic breast cancer.

EMERALD: Elacestrant in ER+/HER2- Advanced Breast Cancer

January 23rd 2024

Kevin Kalinsky, MD, MS, gives an overview of recent data from the EMERALD trial investigating elacestrant in patients with ER+/HER2- advanced breast cancer.

PADA-1 Trial: ctDNA Monitoring for Acquired ESR1 Mutations in Advanced Breast Cancer

January 23rd 2024

Drs Mayer and Kalinsky provide insights and offer their impressions of the PADA-1 trial, focusing on ESR1 mutation monitoring with circulating tumor DNA (ctDNA).

Dr Advani on the Role of Capivasertib Plus Fulvestrant in HR+/HER2– Breast Cancer

January 23rd 2024

Pooja Advani, MBBS, MD, discusses the potential utilization of capivasertib plus fulvestrant in hormone receptor–positive, HER2-negative breast cancers with PIK3/AKT/PTEN pathway alterations.

NICE Recommends Talazoparib for Advanced BRCA1/2-Mutant, HER2– Breast Cancer

January 22nd 2024

NICE has recommended talazoparib for the treatment of patients with advanced or metastatic HER2-negative breast cancer with germline BRCA1/2 mutations.

Laying the Foundation for an Improved HR+/ HER2- Breast Cancer Treatment Paradigm

January 22nd 2024

Investigators continue to evaluate HER2 expression as well as CDK4/6 inhibitor use for hormone receptor–positive/HER2-negative breast cancer.

Dr Meisel on the Impact of Endocrine Therapy–Related Toxicities on QOL in ER+/HER2– Breast Cancer

January 19th 2024

Jane L. Meisel, MD, discusses the impact of toxicities associated with endocrine therapy on quality of life as reported by patients with metastatic breast cancer.

The Role of Genetics in Cancer Care Continues to Expand

January 18th 2024

Genetic screening and testing have only recently become an integral part of cancer care.

AURKA Pathway Gains Ground as Targetable Option in Metastatic Breast Cancer

January 17th 2024

As novel drugs targeting the AURKA pathway continue to advance through the development pipeline, alisertib has emerged as an agent of particular note.

Dr Brufsky on Unmet Needs and Unanswered Questions in HR+/HER2– Breast Cancer

January 16th 2024

Adam M. Brufsky, MD, PhD, FACP, discusses the remaining questions following the FDA approval of capivasertib/fulvestrant in HR+/HER2- breast cancer.